Followers | 55 |
Posts | 2608 |
Boards Moderated | 0 |
Alias Born | 02/04/2014 |
Wednesday, December 30, 2015 5:12:04 PM
SOURCE Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, N.Y., Dec. 30, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
John S. Kovach M.D., founder and president of Lixte, said "LB-100 is a novel small molecule that in preclinical studies has activity against a number of different cancer types alone and, most prominently, in combination with cytotoxic drugs, including some known to be active against hepatocellular carcinoma. We welcome an opportunity to work with an outstanding group of investigators in Taiwan to assess the value of LB-100 against this all-too-common and devastating cancer."
HCC is the fifth most common cancer and third most common cause of cancer deaths worldwide, with the majority of those deaths in Asia. The World Cancer Research Fund International reported that 782,000 new cases were diagnosed in 2012 worldwide. There are approximately 35,000 new cases and 24,000 deaths from HCC annually in the US according to the National Cancer Institute.
Taipei Medical University has nine colleges, thirteen undergraduate schools, fifteen graduate institutes, as well as three affiliated hospitals with approximately three thousand beds. TMU is one of the largest health care systems in Taipei, providing teaching, research and clinical services. In 2012 they established the Taipei Cancer Center, the first world-class cancer center in Taiwan, combining cancer research, training and clinical treatment, dedicated to providing the full spectrum of services for adult and pediatric oncology.
http://www.newson6.com/story/30852953/lixte-biotechnology-holdings-inc-announces-exclusive-licensing-of-their-lead-anti-cancer-compound-lb-100-for-potential-treatment-of-hepatocellular
Recent LIXT News
- LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” • GlobeNewswire Inc. • 05/08/2024 01:25:00 PM
- Mixed Shelf Filing Gives Micro Cap Delayed Boost • AllPennyStocks.com • 04/24/2024 07:25:00 PM
- Biotech Steals The Show Following Pre-Clinical Data Announcement • AllPennyStocks.com • 03/27/2024 07:35:00 PM
- NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:59:41 PM
- Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 03:48:13 PM
- LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI • GlobeNewswire Inc. • 02/26/2024 01:30:00 PM
- First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:21:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 07:28:17 PM
- LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations • GlobeNewswire Inc. • 11/13/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:27:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 06:51:08 PM
- LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration • GlobeNewswire Inc. • 10/16/2023 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/10/2023 07:55:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/10/2023 07:47:19 PM
- LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach • GlobeNewswire Inc. • 10/09/2023 12:30:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 10/06/2023 12:39:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 12:36:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 10:10:01 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/29/2023 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 10:15:20 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM